Physician profile
Michael S Painter
NPI 1164807178
$1,714.72
in general payments reported to CMS, 2019-2025
23 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.74 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323.46 | 2021-2025 | |
| Novo Nordisk INC | $224.07 | 2025 | Rybelsus, Ozempic, Wegovy |
| Axsome Therapeutics, INC. | $187.53 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.18 | 2025 | Caplyta |
| Lilly USA, LLC | $107.87 | 2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $88.73 | 2025 | Veozah |
| Amgen INC. | $78.04 | 2025 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $75.35 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $73.67 | 2025 | |
| Corium, LLC | $60.99 | 2025 | Azstarys |
| Electromed, INC. | $52.32 | 2025 | Smartvest |
| Glaxosmithkline, LLC. | $48.42 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $33.79 | 2025 | Breztri |
| Collegium Pharmaceutical, INC. | $31.77 | 2025 | Jornay Pm |
| Tonix Medicines, INC. | $31.37 | 2025 | Tonmya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $26.60 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.56 | 2025 | Jardiance |
| Aimmune Therapeutics, INC. | $24.54 | 2025 | Zenpep |
| Abbott Laboratories | $21.51 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $17.92 | 2025 | Cologuard Collection Kit |
| Verona Pharma, INC. | $16.92 | 2025 | Ohtuvayre |
| Antares Pharma, INC. | $15.88 | 2025 | Xyosted |
| Organon LLC | $15.23 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Painter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.